Trial Profile
Recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide (1018 ISS) provides superior protection in older subjects.
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary) ; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Pharmacodynamics
- 05 Nov 2010 New trial record.